SignaCor: Funding, Investors & Team (Oct 2026)
SignaCor is a clinical-stage biotech company exploring therapeutics for cardiac disorders, specifically hypertrophic cardiomyopathy.
SignaCor has raised $330k across 1 funding round on record, the most recent a Seed of $330k announced in Mar 2026.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
SignaCor Company Profile and Key Stats
Latest funding round on record: Mar 2026.
SignaCor Funding Rounds
SignaCor Founders and Leadership Team
Contact details for the SignaCor team: 1 has a LinkedIn profile.
Start 14-day free trial →SignaCor Funding Compared to Other Biotechnology Startups
SignaCor's latest round of $330k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Biotechnology Startups Like SignaCor
Companies Similar to SignaCor
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergy…
BioLinker is a creation of manufactured science, protein blend packs, and protein.
WhiteLab Genomics develops digital tools that help gene and cell therapy companies develop cheaper drugs…
Tydra Labs is a biotechnology company that transforms crustacean shell waste into chitin and bio-products.
M-Based develops new alternative material technologies using mushrooms. 🍄 We consider environmental…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
SignaCor Funding FAQs
What does SignaCor do?
SignaCor is a clinical-stage biotech company exploring therapeutics for cardiac disorders, specifically hypertrophic cardiomyopathy.
How much funding has SignaCor raised?
SignaCor has raised $330k across 1 round on record. The most recent is a Seed of $330k announced in Mar 2026.
When did SignaCor last raise funding?
SignaCor's most recent funding round on record is a Seed of $330k, announced in Mar 2026.
Who founded SignaCor?
FundedIQ lists Darach Neeson (Founder) at SignaCor.
How many employees does SignaCor have?
SignaCor is in the 1-10 employee band.
How does SignaCor's funding compare to other Biotechnology startups?
SignaCor's latest round of $330k is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's SignaCor Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for SignaCor is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.